Kazia on Wednesday announced positive preclinical data for its paxalisib drug in triple-negative breast cancer. The company's ...

A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, ...

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On June 5, 2025, Kazia Therapeutics announced the dosing of the first patient in a Phase ...

Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the ...

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing ...